** Shares of lab operator Quest Diagnostics DGX.N rise as much as 7% to an over three-year high of $166.39
** Co's Q4 adj EPS of $2.23 beats Wall Street estimates of $2.19 - data compiled by LSEG
** DGX's Q4 revenue of $2.62 bln is above estimates of $2.58 bln
** Co expects 2025 revenue between $10.70 and $10.85 bln, above estimates of $10.67 bln
** Shares of peer Labcorp LH.N up 4.8%
** DGX shares rose 9.4% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。